Alcoholic liver disease (ALD) is associated with changes in the intestinal microbiota. Functional consequences of alcoholassociated dysbiosis are largely unknown. The aim of this study was to identify a mechanism of how changes in the intestinal microbiota contribute to ALD. Metagenomic sequencing of intestinal contents demonstrated that chronic ethanol feeding in mice is associated with an over-representation of bacterial genomic DNA encoding choloylglycine hydrolase, which deconjugates bile acids in the intestine. Bile acid analysis confirmed an increased amount of unconjugated bile acids in the small intestine after ethanol administration. Mediated by a lower farnesoid X receptor (FXR) activity in enterocytes, lower fibroblast growth factor (FGF)-15 protein secretion was associated with increased hepatic cytochrome P450 enzyme (Cyp)-7a1 protein expression and circulating bile acid levels. Depletion of the commensal microbiota with nonabsorbable antibiotics attenuated hepatic Cyp7a1 expression and reduced ALD in mice, suggesting that increased bile acid synthesis is dependent on gut bacteria. To restore intestinal FXR activity, we used a pharmacological intervention with the intestine-restricted FXR agonist fexaramine, which protected mice from ethanol-induced liver injury. Whereas bile acid metabolism was only minimally altered, fexaramine treatment stabilized the gut barrier and significantly modulated hepatic genes involved in lipid metabolism. To link the beneficial metabolic effect to FGF15, a nontumorigenic FGF19 variant-a human FGF15 ortholog-was overexpressed in mice using adeno-associated viruses. FGF19 treatment showed similarly beneficial metabolic effects and ameliorated alcoholic steatohepatitis. Conclusion: Taken together, alcohol-associated metagenomic changes result in alterations of bile acid profiles. Targeted interventions improve bile acid-FXR-FGF15 signaling by modulation of hepatic Cyp7a1 and lipid metabolism, and reduce ethanol-induced liver disease in mice. (HEPATOLOGY 2018;67:2150-2166.
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A lcohol abuse is the cause for cirrhosis in 50% of patients with end-stage liver disease. (1) Chronic alcohol use is linked to changes in the intestinal microbiota in preclinical models (2) (3) (4) and humans. (5, 6) Alcohol exposure/use oftentimes leads to small intestinal bacterial overgrowth. (3, 7) Recent studies evaluated the link between changes in the microbiota composition and alcoholic liver disease (ALD) progression. Dysbiosis contributes to increased intestinal permeability, which allows microbial products to translocate from the intestinal lumen to the liver. (8, 9) Pathogen-associated microbial patterns bind to pathogen recognition receptors in the liver to increase liver inflammation and hepatocyte death. (10, 11) Beyond changes in gut barrier function, chronic ethanol administration also changes the function of the intestinal microbiota. The biosynthesis of saturated fatty acids is decreased in intestinal bacteria, which contributes to gut barrier dysfunction. (12) Bile acids are synthesized, conjugated to glycine or taurine in hepatocytes, and secreted by the biliary system into the duodenum. Conjugated bile acids are present in mixed micelles and have lipid-emulsifying functions. Conjugated bile acids are absorbed by the apical sodium-dependent bile acid transporter (ASBT) into enterocytes of the distal ileum. Conjugated bile acids bind to farnesoid X receptor (FXR) in the intestine to induce endocrine hormone fibroblast growth factor (FGF)-15 (FGF19 in humans), which decreases the transcription of cytochrome P450 enzyme (Cyp)7a1 in hepatocytes thereby limiting de novo synthesis of bile acids. (13, 14) Primary conjugated bile acids are dehydroxylated and deconjugated by intestinal bacteria in the colon and the small intestine. (15) Secondary bile acids are then absorbed (predominantly) passively and can return to the liver through the enterohepatic circulation. FGF19 lowers body weight and protects from diet-induced obesity by suppressing hepatic lipogenesis and increasing hepatic fatty acid oxidation. (16) Germ-free mice show alterations in their bile acid profiles supporting an important role of the gut microbiota for bile acid metabolism. (17) Chronic alcohol consumption is associated with changes in bile acid profiles in patients. Serum-conjugated deoxycholic acid (DCA) and chenodeoxycholic acid were increased and decreased, respectively, in active drinkers without liver disease as compared with healthy controls. (18) Total and secondary bile acids were increased in fecal samples of active drinkers. (18) Using metagenomics and bile acid analysis, we investigated the effects of chronic ethanol administration on the metabolic function of the intestinal microbiota.
Materials and Methods

MICE
Wild-type (WT) C57BL/6 mice (Charles River, Wilmington, MA) were fed a Lieber DeCarli alcohol or isocaloric control diet for 8 weeks starting at 8-10 weeks of age. The Lieber DeCarli alcohol diet consisted of Micro Stabilized Rod Liq AC IRR (LD101A; and Maltodextrin IRR [9598] for the first week) from TestDiet (St. Louis, MO) and 200 Proof Ethanol from Gold Shield (Hayward, CA) in a specific combination following the manufacturer's feeding directions. In brief, the caloric intake from ethanol was 0% on day 1, 10% on days 2 and 3, 20% on days 4 and 5, 30% from day 6 until the end of 6 weeks, and 36% for the last 2 weeks. Mortality of alcohol-fed mice was less than 25% in each ethanol-fed group. Pair-fed control mice received a diet with an isocaloric substitution of dextrose (LD101; TestDiet).
For the antibiotics study, antibiotic treatment was started at 4 weeks after start of liquid diet feeding, and mice were gavaged daily until harvesting. The composition of the antibiotics mixture has been described (polymyxin B [150 mg/kg body weight fBWg/day; McKesson, San Francisco, CA] and neomycin [200 mg/kg BW/day Sigma-Aldrich, St. Louis, MO]). (8) Fexaramine was synthesized following the protocol outlined in Nicolaou et al. (19) by TBJ Chemical Consultant Company (San Diego, CA). Structure and purity of fexaramine (98.0%) were confirmed by nuclear magnetic resonance, high-performance liquid chromatography, and liquid chromatography/mass spectrometry (LC-MS) analyses, as well as by carbon, hydrogen, and nitrogen elemental analyses. Fexaramine (100 mg/kg BW) was diluted in corn oil and gavaged daily during 8 weeks of alcohol feeding. Corn oil served as vehicle control. For the AAV-M52 study, an adeno-associated virus (AAV; AAV2/9 serotype with EF1a promoter; NGM Bio, San Francisco, CA) expressing the human nontumorigenic FGF19-variant M52 (U.S. patent US8951966B2), was injected into mice. Then, 3 3 10 11 vector genomes of AAV per mouse was injected once into the tail vein in a volume of 100 lL per mouse. AAV expressing green fluorescent protein (GFP; NGM Bio) was used as control. AAV was injected 3 weeks after isocaloric or ethanol feeding was started. Age-matched female mice were used throughout the experiments. All animal studies were reviewed and approved by the Institutional Animal Care and Use Committee of the University of California, San Diego (San Diego, CA).
METAGENOMIC SEQUENCING
High-molecular-weight genomic DNA (gDNA) was extracted and purified from the ceca of alcohol and control animals. (3) Metagenomic sequencing and analysis was performed as described. (12) In brief, shotgun libraries were sequenced using an Illumina HiSeq 2000 platform (Illumina, San Diego, CA). After removing reads matching the MGSCv37/mm9 mouse genome assembly, filtered sequences were assembled into contigs and uploaded to the Metagenomics Analysis Server (MG-RAST) at metagenomics.anl.gov for annotation and metabolic reconstruction. (20) The MG-RAST KEGG Mapper was used under default settings to display differential abundances of enzymes involved in metabolism. Data can be accessed through MG-RAST. Sequence reads have been deposited under National Center for Biotechnology Information (NCBI) BioSamples SAMN02671702-SAMN02671718 under BioProject PRJNA89097. (12) 
BILE ACID QUANTIFICATION
Bile acids in liver, plasma, intestinal contents, urine, and feces in WT mice fed an isocaloric or ethanol containing diet for 8 weeks as well as bile acids in intestinal contents in fexaramine-treated (or corn oil-treated) mice were quantified by LC-MS as described. (21) (22) (23) Fecal samples and intestinal contents were dried, and equal amounts were processed. Bile acid analysis of plasma samples of mice treated with antibiotics or fexaramine was performed as follows. Serum (20 lL) was protein precipitated with 80 lL of cold acetonitrile containing deuterated cholic acid (CA) as an internal standard, vortexed for 1 minute, and centrifuged at 10,000 rpm for 10 minute at 48C. Supernatant was evaporated under vacuum and reconstituted in assay mobile phase. Bile acid separation was achieved using an Acuity (Waters, Milford, MA) UPLC BEH C18 column (1.7 microns 2.1 3 100 mm) on a Nextera UPLC (Shimadzu, Tokyo, Japan); the temperature of the column and auto sampler was 658C and 128C, respectively. Sample injection volume was 1 lL. The mobile phase consisted of 10% acetonitrile and 10% methanol in water containing 0.1% formic acid (Mobile Phase A) and 10% methanol in acetonitrile 0.1% formic acid (Mobile Phase B) delivered as a gradient: 0-to 5-minute Mobile Phase B held at 22%; 5-to 12-minute Mobile Phase B increased linearly to 60%; 12-to 15-minute Mobile Phase B increased linearly to 80%; and 15-to 19-minute Mobile Phase B constant at 80% at a flow rate of 0.5 mL/min. The mass spectrometer (Q-Trap 5500; Sciex, Framingham, MA) was operated in negative electrospray mode working in the multiple reaction mode (MRM). Operating parameters were: curtain gas, 30 pounds per square inch (psi); ion spray voltage, 4,500 V;
temperature, 5508C; ion source gas 1, 60 psi; and ion source gas 2, 65 psi. Transition MRMs, declustering potential, entrance potentials, and collision cell exit potentials were optimized using the Analyst software (Sciex, Framingham, MA). Dwell times were 25 msec.
RNA SEQUENCING
RNA was extracted from mouse tissue using Trizol (Invitrogen, Carlsbad, CA). RNA was digested with DNase using the DNA-free DNA removal kit (Ambion, Carlsbad, CA). Library generation and sequencing was performed as described. (24) In brief, sequencing libraries were prepared from total RNA using the TruSeq RNA Sample Preparation Kit v2 (Illumina, San Diego, CA), followed by 100-base-pair single-ended sequencing on the Illumina HiSeq 2500. Image analysis and base calling were performed with Illumina CASAVA-1.8.2, whereas read alignment and junction finding was accomplished using STAR. (25) Gene expression analysis, statistical testing, and annotation was performed using Cuffdiff 2, (26) utilizing UCSC GRCm38/mm10 as the reference assembly. Transcript expression was calculated as gene-level relative abundance in fragments per kilobase of exon model per million mapped fragments and utilized correction for transcript abundance bias. (27) RNA sequencing (RNA-Seq) data reported in this article have been deposited in the NCBI Sequence Read Archive (SRA) database, Accession # SRP100462.
STATISTICAL ANALYSIS
The unpaired Student t test was used for statistical analysis for all graphs where only two groups were being compared, or analysis of variance followed by the Newman-Keuls test for comparison of more than two groups (Prism; GraphPad Software Inc., La Jolla, CA). Results are presented as mean 6 SEM. A P value < 0.05 was selected as the level of significance.
Other materials and methods are described in the Supporting Materials and Methods section.
Results
CHRONIC ETHANOL FEEDING DISRUPTS THE ENTEROHEPATIC CIRCULATION OF BILE ACIDS AND REDUCES INTESTINAL FXR ACTIVITY
To determine functional differences of the intestinal microbiota, metagenomic sequencing was performed following chronic ethanol feeding. Metagenomic analysis revealed that bacterial gDNA encoding choloylglycine hydrolase (CGH [EC 3.5.1.24]) is more abundant in intestinal contents of mice fed ethanol than in controls (Fig. 1A) . Bacterial choloylglycine hydrolase is responsible for the deconjugation (deamidation) of conjugated (amidated) bile acids (Fig. 1A) . (28) Based on our sequencing results, choloylglycine hydrolase was mainly expressed in Lactobacillus, Lactococcus, Bacteroides, and Pediococcus. As we have published, the metagenomic data set also demonstrated reduced levels of the FabG, FabF, and FabD genes (Fig. 1A) , which are involved in fatty acid metabolism. (12) To assess whether changes in the metagenome associated with chronic alcohol feeding directly translate into changes of bile acid profiles, bile acid analysis using MS were performed. Enhanced deconjugation increased levels of unconjugated bile acids in the ileum In particular, proportions of taurine-conjugated cholic acid (TCA) and deoxycholic acid (TDCA) decreased, whereas CA, total muricholic acid (MCA), and DCA increased, in the ileum after ethanol administration (Fig. 1C) . Deconjugated bile acids-in particular, monohydroxy and most dihydroxy bile acids-are rapidly absorbed mostly by nonionic diffusion in the intestine, leading to augmented unconjugated and total bile acid concentrations in the plasma of alcohol-fed mice (Fig. 1D) . Following reuptake into hepatocytes, unconjugated bile acids are rapidly conjugated, resulting in significantly higher hepatic concentrations of conjugated and total bile acids after chronic ethanol feeding (Fig. 1D) . Similarly, the concentration of bile acids in the gallbladder (Fig. 1E ) and the gallbladder weight (Supporting Fig. S1A ) were elevated in the alcohol-fed group. Gallbladder bile acid composition was not changed by alcohol feeding (Supporting Fig.  S1B ). Amounts and composition of fecal bile acids were similar between isocaloric and ethanol-fed mice as were urine bile acids ( Fig. 1F and Supporting Fig.  S1C ). Alcohol feeding also resulted in an increased total bile acid pool (Fig. 1G) . FXR activity can be induced by conjugated bile acids (29) and, to some degree, by TCA. (30) Likely mediated by a lower FXR activity in enterocytes of the terminal ileum resulting from a lower percentual concentration of conjugated bile acids and the significantly lower TCA in the ileum, less FGF15 protein was detected in the ileum (Supporting Fig. S2 ) and secreted into the plasma of ethanol-fed mice (Fig. 1H) . As the rate-limiting enzyme for bile acid synthesis in the liver Cyp7a1 is regulated by negative feedback mechanism via FGF15. (31) We observed increased hepatic Cyp7a1 protein expression (Fig. 1I) , which likely contributes to increased total plasma and hepatic bile acids following chronic ethanol feeding (Fig. 1D ). Protein expression of other enzymes involved in bile acid synthesis (Cyp8b1 and Cyp27a1) were not affected by alcohol feeding (Supporting Fig. S3A ). Conjugated bile acids activate the sphingosine-1-phosphate receptor 2, which activates the protein kinase B (Akt) and extracellular signal-regulated protein kinases 1 and 2 (Erk1/ 2) signaling pathways. (32) Although hepatic bile acid composition changed, phosphorylation of Erk1/2 and Akt in liver was not altered following chronic ethanol administration (Supporting Fig. S3B ). Alkaline phosphatase (not shown) and total bilirubin concentrations (Supporting Fig. S3C ) were not increased in the alcohol-fed group when compared with the isocaloric control group, indicating absence of cholestasis in ethanol-treated mice. Hepatic bile acid transporters such as Ntcp or Bsep as well as intestinal bile acid transporters such as Asbt were not affected by alcohol feeding (Supporting Fig. S4A,B) . Thus, chronic ethanol administration disrupts the negative feedback loop on bile acid synthesis, and despite elevated systemic bile acids, hepatocytes continue to generate bile acids. In addition, changes in the bile acid composition are observed after chronic ethanol feeding.
DISRUPTION OF THE ENTEROHEPATIC CIRCULATION DEPENDS ON THE INTESTINAL MICROBIOME IN ALD
We then attempted to restore bile acid homeostasis. Our first approach was to target intestinal dysbiosis and eradicate commensal microbes in the intestine with nonabsorbable antibiotics. We have reported that polymyxin B and neomycin abolished intestinal bacterial overgrowth and decreased liver injury and steatosis, but did not affect intestinal absorption of ethanol. (8) Here, we demonstrate that oral antibiotics decreased hepatic Cyp7a1 expression ( Fig. 2A) and restored systemic bile acid levels (Fig. 2B) . In addition to reversing increased total plasma bile acids following chronic ethanol feeding, antibiotics had a profound effect on plasma bile acid composition following chronic ethanol administration. There was a general increase in conjugated bile acids and in particular, an increase of TCA and taurine-conjugated beta-MCA (Fig. 2C) . Inhibition of intestinal FXR resulted in decreased ceramide signaling in a high-fat diet-induced nonalcoholic fatty live disease (NAFLD) mouse model. This downregulated hepatic fatty acid synthesis-related genes, such as sterol response element-binding protein 1c (Srebp1c) and DNA fragmentation factor a-like effector A (Cidea), leading to reduced hepatic steatosis. (30) Srebp1 and Cidea gene expression was not affected by antibiotics (Supporting Fig. S5 ). These results support our metagenomic and bile acid analysis and suggest that increased bile acid synthesis is dependent on the intestinal microbiome. Furthermore, the known beneficial effect of intestinal decontamination on ALD might not only be mediated by reducing intestinal bacterial overgrowth and translocation of bacterial products, but also by changing plasma bile acid profiles.
THE INTESTINE-RESTRICTED FXR AGONIST FEXARAMINE ALLEVIATES ETHANOL-INDUCED LIVER DISEASE
Our findings suggest that chronic ethanol intake induces dysbiosis and modulates bile acids, resulting in lower intestinal FXR signaling and increased plasma bile acids. Our second intervention approach aimed at restoring intestinal FXR signaling. We therefore investigated whether treating mice with an intestine-specific FXR agonist prevents ethanol-associated liver disease in mice. We used the synthetic FXR agonist fexaramine which is not absorbed after oral gavage and does not show systemic FXR stimulation. (24) Daily gavage of fexaramine reduced ethanol-induced liver injury (as demonstrated by lower plasma alanine aminotransferase [ALT] levels) and steatosis (Fig. 3A-D) . Ethanolinduced hepatic inflammation, as evidenced by increased hepatic interleukin (IL)-1B and tumor necrosis factor (TNF) protein, was decreased in liver of fexaramine-treated mice (Fig. 3E,F) .
After absorption in the gastrointestinal tract, ethanol is metabolized in the liver by alcohol-dehydrogenase 1 (Adh1) and the inducible Cyp2e1. Intestinal ethanol absorption or hepatic ethanol metabolism by Adh1 and Cyp2e1 was not affected after activation of FXR in the intestine (Supporting Fig. S6A-C) .
FXR induces antimicrobial molecules in intestinal epithelial cells (29) and protects from intestinal barrier dysfunction. (24) Fexaramine did not affect the total amount of bacteria in the cecum after ethanol administration (Supporting Fig. S7A ). Ethanol is known to disrupt enteric tight junctions and induce intestinal barrier dysfunction. (33) We have confirmed this by measuring fecal albumin and the intestinal tight junction protein occludin (Supporting Fig. S7B,C) . Fexaramine treatment maintained intestinal barrier integrity, as determined by reduced fecal albumin levels and a higher intestinal occludin protein expression than vehicle-treated mice after ethanol feeding (Supporting Fig. S7B,C) . This is associated with lower inflammatory cytokine expression such as Tnf and Il1b in the ileum (Supporting Fig. S7D ). Dysbiosisinduced intestinal inflammation mediated by TNF is known to disrupt the intestinal barrier and contribute to ALD. (8) It is therefore possible that fexaramineinduced FXR activity, as evidenced by increased small heterodimer partner (Shp) protein in the intestine (Supporting Fig. S7E ), reduces intestinal inflammation and stabilizes the gut barrier.
FEXARAMINE MINIMALLY AFFECTS BILE ACID METABOLISM (SYNTHESIS AND INTERCONVERSION) FOLLOWING CHRONIC ETHANOL ADMINISTRATION, BUT ENHANCES LIPID CATABOLISM AND REPRESSES SYNTHESIS OF LIPIDS IN THE LIVER
Next, we assessed the effect of intestinal FXR activation on bile acid synthesis and composition. Administration of fexaramine increased plasma FGF15 protein concentrations (Fig. 4A ) and suppressed hepatic Cyp7a1 protein expression following chronic ethanol feeding (Fig. 4B,C) . Hepatic expression of Cyp8b1 mRNA was not modulated by chronic ethanol diet or by fexaramine administration (Fig. 4D) . Surprisingly, total plasma bile acids were not significantly different in fexaramine-treated mice after chronic ethanol feeding (Fig. 4E) . Similarly, plasma bile acid profiles were not changed dramatically. In mice fed ethanol, fexaramine treatment resulted in a slight increase in plasma omega-MCA and a small decrease of plasma CA (Fig. 4F) . Taken together, an intestinespecific FXR agonist protects from ethanol-induced liver disease in mice. Intestinal FXR activation stabilizes the gut barrier, but affects plasma bile acids only minimally following chronic ethanol administration.
To gain additional insight into the beneficial effect of fexaramine, RNA-Seq of liver tissue was performed (Fig. 5A) . Pathway analysis demonstrated activation of multiple pathways in fexaramine-treated mice after ethanol feeding. Differentially regulated pathways included lipid and carbohydrate metabolism (Fig. 5B) . Functional analyses of liver transcriptomes revealed that genes involved in triglyceride biosynthesis were down-regulated, including fatty acid synthase (Fasn), elongation of long chain fatty acids family member 6 (Elovl6), and Lipin1 (Lpin1), whereas nuclear receptor subfamily 1, group D, member 1 (Nr1d1; also called rev-erbA alpha) as inhibitor of lipogenesis was increased. This is in line with the lower hepatic triglyceride contents following fexaramine treatment. Up-regulated genes in the lipolysis pathway, including lipoprotein lipase (Lpl), contribute to the lipid catabolic effect observed. In addition, fexaramine treatment induced the expression of genes involved in betaoxidation, including pyruvate dehydrogenase kinase, isoenzyme 4 (Pdk4), and acyl-CoA thioesterase 2 (Acot2; Fig. 5C ). Activation of similar metabolic pathways was observed after overexpression of FGF15 in a model of diet-induced obesity in mice. (16) The hepatic fatty acid synthesis-related genes Srebp1 and Cidea were not affected by fexaramine treatment (Supporting Fig. S8 ). Overall, these findings, combined with minimal changes in bile acid metabolism, are suggestive of a specific role for FGF15 in mediating the metabolic effect of intestinal FXR activation.
THE HUMAN FGF19-VARIANT M52 INCREASES LIPID CATABOLISM, SUPPRESSES ANABOLISM OF LIPIDS, AND MITIGATES ALCOHOLIC STEATOHEPATITIS
To investigate the proposed role of FGF15 for mediating the beneficial effect of fexaramine, we used AAV overexpression of a human FGF15 ortholog, the nontumorigenic FGF19-variant M52 (AAV-M52). AAV-M52-injected mice were protected from ethanolinduced liver injury, as demonstrated by lower levels of plasma ALT as compared with control mice injected with GFP-expressing AAV (Fig. 6A) . AAV-M52 showed a dramatic effect on hepatic triglycerides; AAV-M52 decreased liver triglycerides in isocaloric and ethanol-fed mice to a significantly lower concentration than observed in AAV-GFP-injected mice (Fig. 6B-D) . Hepatic inflammatory markers IL1B and TNF were reduced in AAV-M52-treated mice (Fig. 6E,F) . Absorption of ethanol and hepatic metabolism of ethanol were not affected by AAV-M52 injection (Supporting Fig. S9A-C) . Plasma M52 concentrations were similar in both AAV-M52-injected mouse groups (Supporting Fig. S9D ).
Although overexpression of M52 reduced hepatic Cyp7a1 protein and Cyp8b1 mRNA expression following ethanol administration (Fig. 7A,B) , plasma bile acid concentrations were similar in ethanol-fed AAV-M52-and AAV-GFP-injected mice (Fig. 7C) . The reason for increased conjugated, in particular taurineconjugated bile acids in isocaloric-fed mice injected with AAV-M52 is not known (Fig. 7C) . Mice injected 2162 with AAV-M52 had markedly lower plasma levels of DCA and TDCA (Fig. 7D ). This could contribute to hepatic protection, given that DCA has been shown to be toxic to hepatocytes. (34, 35) To further clarify the role of FGF19 in preventing alcoholic steatohepatitis, we compared transcriptional hepatic changes in mice injected with AAV-M52. Notably, overexpression of M52 caused similar transcriptional metabolic changes associated with fexaramine treatment. Specifically, there was a very strong suppression of triglyceride biosynthesis, whereas lipolysis was activated in M52-overexpressing mice following ethanol feeding (Fig. 7E) . The hepatic fatty acid synthesis-related genes Srebp1 and Cidea were not affected by AAV-M52 when alcohol-fed groups were compared (Supporting Fig. S9E ). Transcriptional changes in lipid metabolism were stronger in mice overexpressing M52 as compared with fexaramine-treated mice. Collectively, these results suggest that intestinal FXR activation and FGF19 overexpression induce similar transcriptional changes involving lipid catabolism that contribute to protection from alcoholic steatohepatitis in mice.
Discussion
ALD is associated with changes in the intestinal microbiota composition in animal models and humans. (36, 37) Although taxonomic changes of the fecal-and mucosa-associated microbiota have been characterized in patients with alcohol abuse, (5, 6) functional consequences are not well understood. Using metagenomics and bile acid analysis, we demonstrate that chronic alcohol administration is associated with an increase in bacterial choloylglycine hydrolase, which deconjugates bile acids in the intestine of mice. This is accompanied by a lower FGF15 protein secretion from enterocytes in the small intestine and increased hepatic bile acid synthesis. Total plasma and hepatic bile acid concentrations were elevated after chronic ethanol feeding, which likely synergizes with ethanol to cause hepatocyte death.
Bile salt hydrolases of the choloylglycine hydrolase family (EC 3.5.1.24) mediate deconjugation of bile acids. (15) Our metagenomic analysis showed increased choloylglycine hydrolase after alcohol feeding. It did not show genomic differences in other enzymes involved in bile acid metabolism in intestinal bacteria. However, we cannot rule out that there are other genes encoded by the intestinal microbiota that contribute to changes in bile acid metabolism associated with chronic ethanol feeding. Alcoholics with cirrhosis show increased hepatic bile acid secretion compared with healthy controls, (38) similar to what we demonstrated in alcohol-fed mice in this study. Alcoholics with cirrhosis have also been found to have higher fecal concentrations of hepatotoxic DCA and increased secondary to primary bile acid ratios in relation to healthy controls. (38) The initiating/central role of the intestinal microbiome in alcohol-related disturbances of bile acid homeostasis has been demonstrated using humanized gnotobiotic mice. (39) Germ-free mice transplanted with stool from patients with cirrhosis with active alcoholism showed a higher ability to deconjugate and produce secondary bile acids in the stool with subsequent derangements of the bile acid homeostasis in several organs than germ-free mice transplanted with stool from healthy subjects, (39) similar to the human subjects themselves. (38) This supports the importance of the deconjugating choloylglycine hydrolase family in the development of ALD. In addition to intestinal dysbiosis and bacterial overgrowth, (3) a prolonged intestinal transit time associated with alcohol abuse (40) might contribute to increased deconjugation of bile acids.
Nonabsorbable antibiotics are known to ameliorate preclinical ethanol-induced liver disease when used as a prevention (41) or intervention. (8) Although it is commonly thought that intestinal decontamination reduces intestinal bacterial overgrowth, stabilizes the gut barrier, and decreases translocation of bacterial products to the liver, (8) broad-spectrum antibiotics neomycin and polymyxin B affect bile acid metabolism. Hepatic bile acid synthesis is suppressed and systemic total bile acid concentrations are reduced. Lowering bile acid levels protects from ethanol-induced liver disease, because bile acids are detergents and can be toxic to hepatocytes. In addition, antibiotics cause a shift toward more conjugated and hence less toxic bile acids. There was also a large decrease in DCA in the presence of antibiotics. DCA is known to be more liver toxic than CA. (34) Thus, antibiotics are beneficial for experimental ethanol-induced liver disease by not only stabilizing the intestinal barrier but also by inhibiting deconjugation of bile acids in the intestine and creating a less hepatotoxic bile acid composition. However, the choice of antibiotics is also important: a cocktail of four antibiotics (ampicillin, neomycin, metronidazole, and vancomycin) improved hepatic inflammation and steatosis but did not protect from alcohol-induced increases of ALT/AST aspartate aminotransferase. (42) Furthermore, the nonabsorbable broad-spectrum antibiotic paromomycin failed to improve ALD in patients. (43) Since different antibiotics have various effects on systemic bile acid composition and concentrations as well as on ALD in general, antibiotics have to be carefully selected for future clinical trials.
It has been shown that deficiency or inhibition of intestinal FXR (by administration of glyco-beta-MCA, tauro-beta-MCA, or tempol) alleviates obesity and NAFLD in mice. (44, 45) However, in ALD, deficiency of FXR worsens liver damage, (46, 47) and agonizing FXR activity systemically improves ALD. (46) Furthermore, glyco-/tauro-beta-MCA induced changes of the ceramide/Srebp1c/Cidea axis were observed in obesity and NAFLD. (30, 45) These pathways do not appear to play a central role in ALD, given that there were no significant differences in hepatic expression of Srebp1 or Cidea after alcohol feeding in any of our experiments, nor did our pharmacological interventions change the expression when compared with their alcohol-fed control.
Administration of the systemic FXR agonist WAY-362450 ameliorates ethanol-induced liver disease in mice. (46) This protection is partly mediated by suppression of hepatic Cyp2e1 expression, (46) which is known to decrease ethanol-induced liver injury. (48) Although intestinal FXR activation suppressed hepatic Cyp7a1 expression, it did not suppress systemic bile acids and minimally affected plasma bile acid composition. Fexaramine likely has additional effects beyond targeting bile acid synthesis. One beneficial effect is stabilization of the intestinal barrier, which might account for decreased hepatic inflammation that we observed after ethanol treatment. However, transcriptomics demonstrated a prominent effect on hepatic lipid metabolism, which was mimicked by hepatic overexpression of a FGF19 variant. Consistent with our results, FGF15 has been proposed to be downstream of mitoNEET deficiency in mice, which was associated with protection against alcoholic steatohepatitis. (49) Taken together, metagenomics and bile acid analysis demonstrate functional consequences of intestinal dysbiosis following chronic ethanol administration, including low FGF15 plasma levels, increased hepatic Cyp7a1 expression with disturbed bile acid homeostasis, and changed hepatic lipid metabolism. Modulating dysregulated bile acid signaling improves ethanolinduced liver disease in this preclinical model. Fexaramine and FGF19 are therefore candidate drugs to treat alcoholic steatohepatitis in humans. Although long-term toxicity data are currently not available for fexaramine, it has the advantage of being intestinally restricted, thereby potentially avoiding systemic effects observed with systemic FXR agonists such as pruritus. (50) NGM282, a nontumorigenic FGF19 variant similar to M52, has been tested in a phase 2 clinical trial for primary biliary cholangitis (ClinicalTrials.gov Identifier: NCT02704364) and is currently being tested in a clinical trial for nonalcoholic steatohepatitis (ClinicalTrials.gov Identifier: NCT02443116). The exact treatment doses of fexaramine and FGF19 variants have still to be determined to achieve the best benefit with a tolerable side-effect profile.
